Mortality in hepatitis C virus-cured vs. hepatitis C virus-uninfected people with HIV.
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
01 07 2023
01 07 2023
Historique:
medline:
7
11
2023
pubmed:
19
4
2023
entrez:
18
4
2023
Statut:
ppublish
Résumé
It is unknown whether hepatitis C virus (HCV)-cured people with HIV (PWH) without cirrhosis reached the same mortality risk as HCV-uninfected PWH. We aimed to compare mortality in PWH cured of HCV by direct-acting antivirals (DAAs) to mortality in individuals with HIV monoinfection. Nationwide hospital cohort. HIV-controlled participants without cirrhosis and HCV-cured by DAAs started between September 2013 and September 2020, were matched on age (±5 years), sex, HIV transmission group, AIDS status, and body mass index (BMI) (±1 kg/m 2 ) to up to 10 participants with a virally suppressed HIV monoinfection followed at the time of HCV cure ±6 months. Poisson regression models with robust variance estimates were used to compare mortality in both groups after adjusting for confounders. The analysis included 3961 HCV-cured PWH (G1) and 33 872 HCV-uninfected PWH (G2). Median follow-up was 3.7 years in G1 [interquartile range (IQR): 2.0-4.6], and 3.3 years (IQR: 1.7-4.4) in G2. Median age was 52.0 years (IQR: 47.0-56.0), and 29 116 (77.0%) were men. There were 150 deaths in G1 [adjusted incidence rate (aIR): 12.2/1000 person-years] and 509 (aIR: 6.3/1000 person-years) in G2, with an incidence rate ratio (IRR): 1.9 [95% confidence interval (CI), 1.4-2.7]. The risk remained elevated 12 months post HCV cure (IRR: 2.4 [95% CI, 1.6-3.5]). Non-AIDS/non-liver-related malignancy was the most common cause of death in G1 (28 deaths). Despite HCV cure and HIV viral suppression, after controlling on factors related to mortality, DAA-cured PWH without cirrhosis remain at higher risk of all-cause mortality than people with HIV monoinfection. A better understanding of the determinants of mortality is needed in this population.
Identifiants
pubmed: 37070541
doi: 10.1097/QAD.0000000000003569
pii: 00002030-990000000-00240
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1297-1306Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Croxford S, Kitching A, Desai S, Kall M, Edelstein M, Skingsley A, et al. Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohort . Lancet Public Health 2017; 2:e35–e46.
Antiretroviral Therapy Cohort Collaboration. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies . Lancet HIV 2017; 4:e349–e356.
Edwards JK, Cole SR, Breger TL, Rudolph JE, Filiatreau LM, Buchacz K, et al. Mortality among persons entering HIV care compared with the general U.S. population: an observational study . Ann Intern Med 2021; 174:1197–1206.
Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years – United States, 2008. Available at: https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5710a1.htm [Accessed 25 August 2021].
Morlat P, Roussillon C, Henard S, Salmon D, Bonnet F, Cacoub P, et al. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000 . AIDS Lond Engl 2014; 28:1181–1191.
Butt ZA, Wong S, Rossi C, Binka M, Wong J, Yu A, et al. Concurrent hepatitis C and B virus and human immunodeficiency virus infections are associated with higher mortality risk illustrating the impact of syndemics on health outcomes . Open Forum Infect Dis 2020; 7:ofaa347.
Thornton AC, Jose S, Bhagani S, Chadwick D, Dunn D, Gilson R, et al. Hepatitis B, hepatitis C, and mortality among HIV-positive individuals . AIDS Lond Engl 2017; 31:2525–2532.
Alejos B, Hernando V, Iribarren J, Gonzalez-García J, Hernando A, Santos J, et al. Overall and cause-specific excess mortality in HIV-positive persons compared with the general population: role of HCV coinfection . Medicine (Baltimore) 2016; 95:e4727.
Kronfli N, Bhatnagar SR, Hull MW, Moodie EEM, Cox J, Walmsley S, et al. Trends in cause-specific mortality in HIV-hepatitis C co-infection following hepatitis C treatment scale-up . AIDS Lond Engl 2019; 33:1013–1022.
Schlabe S, Rockstroh JK. Advances in the treatment of HIV/HCV coinfection in adults . Expert Opin Pharmacother 2018; 19:49–64.
Carrat F, Fontaine H, Dorival C, Simony M, Diallo A, Hezode C, et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study . Lancet 2019; 393:1453–1464.
Berenguer J, Rodríguez-Castellano E, Carrero A, Von Wichmann MA, Montero M, Galindo MJ, et al. Eradication of hepatitis C virus and nonliver-related nonacquired immune deficiency syndrome-related events in human immunodeficiency virus/hepatitis C virus coinfection . Hepatol Baltim Md 2017; 66:344–356.
Chalouni M, Pol S, Sogni P, Fontaine H, Lacombe K, Jean-Marc-Lacombe, et al. Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to nonliver-related death . J Hepatol 2020; 74:37–47.
Tacke F, Boeker KHW, Klinker H, Heyne R, Buggisch P, Pathil A, et al. Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs . Liver Int 2019; 40:539–548.
Mary-Krause M, Grabar S, Lievre L, Abgrall S, Billaud E, Boue F, et al. Cohort profile: French hospital database on HIV (FHDH-ANRS CO4) . Int J Epidemiol 2014; 43:1425–1436.
Pawlotsky J-M, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, et al. EASL recommendations on treatment of hepatitis C: final update of the series . J Hepatol 2020; 73:1170–1218.
Royall RM. Model robust confidence intervals using maximum likelihood estimators . Int Stat Rev Rev Int Stat 1986; 54:221–226.
Chalouni M, Pol S, Sogni P, Fontaine H, Lacombe K, Marc-Lacombe J, et al. Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to nonliver-related death . J Hepatol 2021; 74:37–47.
Shili-Masmoudi S, Sogni P, de Ledinghen V, Esterle L, Valantin M-A, Poizot-Martin I, et al. Increased liver stiffness is associated with mortality in HIV/HCV coinfected subjects: The French nationwide ANRS CO13 HEPAVIH cohort study . PLoS One 2019; 14:e0211286.
Janjua NZ, Wong S, Abdia Y, Jeong D, Buller-Taylor T, Adu PA, et al. Impact of direct-acting antivirals for HCV on mortality in a large population-based cohort study . J Hepatol 2021; 75:1049–1057.
Tonnerre P, Wolski D, Subudhi S, Aljabban J, Hoogeveen RC, Damasio M, et al. Differentiation of exhausted CD8+ T cells after termination of chronic antigen stimulation stops short of achieving functional T cell memory . Nat Immunol 2021; 22:1030–1041.
Gobran ST, Ancuta P, Shoukry NH. A tale of two viruses: immunological insights into HCV/HIV coinfection . Front Immunol 2021; 12:3192.
D’Ambrosio R, Degasperi E, Anolli MP, Fanetti I, Borghi M, Soffredini R, et al. Incidence of liver- and nonliver-related outcomes in patients with HCV-cirrhosis after SVR . J Hepatol 2022; 76:302–310.
Innes H, McDonald S, Hayes P, Dillon JF, Allen S, Goldberg D, et al. Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population . J Hepatol 2017; 66:19–27.
Santos M, Protopopescu C, Delarocque-Astagneau E, Bourlière M, Petrov-Sanchez V, Di Beo V, et al. Late presentation for HCV care: Time to target people with diabetes and/or hazardous alcohol use (ANRS CO22 HEPATHER cohort) . Liver Int 2022; 42:38–49.
Aleman S, Söderholm J, Büsch K, Kövamees J, Duberg A-S. Frequent loss to follow-up after diagnosis of hepatitis C virus infection: a barrier towards the elimination of hepatitis C virus . Liver Int 2020; 40:1832–1840.
Fursa O, Mocroft A, Lazarus JV, Amele S, Lundgren J, Matulionyte R, et al. The hepatitis C cascade of care in HIV/HCV-coinfected individuals in Europe- regional and intra-regional differences . AIDS 2021; 36:423–435.
Yin X, Kong L, Du P, Jung J. Effects of direct-acting antiviral treatment on reducing mortality among Medicare beneficiaries with HIV and HCV coinfection . AIDS Care 2021; 0:1–8.
Santos ME, Protopopescu C, Sogni P, Yaya I, Piroth L, Bailly F, et al. HCV-related mortality among HIV/HCV co-infected patients: the importance of behaviors in the HCV cure era (ANRS CO13 HEPAVIH Cohort) . AIDS Behav 2019; 24:1069–1084.
Cotte L, Hocqueloux L, Lefebvre M, Pradat P, Bani-Sadr F, Huleux T, et al. Microelimination or not? The changing epidemiology of human immunodeficiency virus-hepatitis C virus coinfection in France 2012–2018 . Clin Infect Dis 2021; 73:e3266–e3274.
Mangia A, Cotugno R, Cocomazzi G, Squillante MM, Piazzolla V. Hepatitis C virus micro-elimination: where do we stand? . World J Gastroenterol 2021; 27:1728–1737.
Loko M-A, Salmon D, Carrieri P, Winnock M, Mora M, Merchadou L, et al. The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006–2010 . BMC Infect Dis 2010; 10:303.